Audrey Kam

Research Director, Gastrointestinal Oncology @RushCancer | Assistant Professor @RushMedical

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[JAMA @JAMA_current]

💬 Editorial by Richard Sullivan, MD, PhD, and Christopher Booth, MD: Blood-based #MCD tests for early #Cancer detection showed no proven population-wide benefit in a major UK trial, with modest diagnostic delays and risk of false-positive results, raising concerns about system strain and patient harm from widespread adoption.

https://t.co/DtMH5eFKi9

#ARM26 @AcademyHealth

[Ignacio Garrido-Laguna @GarridoLagunaMD]

This is huge news!! Game changer @DavidHongMD @ASCOPost @AACR @MoffittNews @huntsmancancer @PanCAN @KRASKickers Kudos to @FDA and @RevMedicines for this expanded access program to give US patients fighting PDAC early access to daraxonrasib. 👏💪🙏https://t.co/elrA2Fznjy

[Keith Siau @drkeithsiau]

You are replaceable at work, but you are NOT replaceable at home. A beautiful and poignant reflection that applies to all clinicians.

[Arndt Vogel @ArndtVogel]

Domvanalimab, zimberelimab, and FOLFOX in advanced GC/GEJC/EAC
#ESMO25 #ESMOAmbassadors
👉 ORR: 59%, TAP>5% 69%
👉 mPFS: 12.9 mo
👉 mOS: 26.7%
🧐Promising efficacy for anti-TIGIT plus anti-PD1
@myesmo

[Mario Balsa @MarioBalsaMD]

👀 #ESMO25 – PERISCOPE II: ph. III trial of gastrectomy + CRS/HIPEC vs systemic therapy alone in GC w/ limited peritoneal M1

🛑 Study stopped early (n=102) for futility
👎🏻 mOS: 15.7 vs 16.6 mo (HR 1.1; p=0.7)
🛑 No survival benefit, notable morbidity

A sobering view from the depths…this PERISCOPE couldn’t find clearer waters 🌊

@OncoAlert #OncoAlertAF @OncoReporte
@myESMO @_SEOM @GrupoTTD

[Erman Akkus @Erman_Akkus]

📢MATTERHORN
Upper GI proffered #ESMO25

✅Significant OS
D + FLOT vs FLOT
HR: 0.78; (95% CI: 0.63–0.96) p=0.021

🧐❓PD-L1 TAP <1%: (HR, 0.79; 95% CI: 0.41–1.50)

#cancer #oncology #MedX #GI #gastrointestinal @OncoAlert @brunolarvol @OncBrothers

[Thor Halfdanarson @OncoThor]

To operate or not on panc NETs <2 cm…? The answer is NOT.

Excellent presentation by @spartelli on the long term outcomes of the ASPEN trial. Almost 1000 patients observed w/o resection and progression was uncommon, mets rare and survival the same as with resection.

[Arndt Vogel @ArndtVogel]

PERISCOPE II trial: Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination
#ESMO25 #ESMOAmbassadors
👉 mOS: 16.6 vs 15.6 mo
🧐no benefit for CRS/HIPEC for pts with limited peritoneal metastasis, significant toxicity
@myesmo

[Erman Akkus @Erman_Akkus]

🟠mFOLFIRINOX vs Gem/Nab-Paclitaxel in 1L treatment of metastatic pancreatic cancer
PASS-01 @JCO_ASCO

❌mPFS: 4 vs 5.3 mo
HR: 1.37 [0.97 to 1.92]; P = .069
✅mOS: 8.5 vs 9.7 mo
HR: 1.57 [1.08 to 2.28]; P = .017

➡️In line with the results of GENERATE trial from Japan
🤔 Does not change the reality that only around less than 1 year survival we can achieve

👉https://t.co/r49yqukXp9

#cancer #oncology #MedX @OncoAlert @realbowtiedoc #pancreatic @ASCO

[Mark Yarchoan @MarkYarchoan]

More disappointing news in #HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 #KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after #IMbrave050

[Dr Amol Akhade @SuyogCancer]

For all those who ask me about
If sugar intake causes cancer ? #CancerAwareness #mythsvsfact

[Nieves Martinez Lago MD PhD @DraMartinezLago]

Omitting bolus 5-FU in GI cancer chemo: a meta-analysis 🔬
https://t.co/OQYRq05S2F
In 12,698 pts, skipping bolus 5-FU ➡️ ↓ grade 3–4 neutropenia (🧪 OR 0.46) & thrombocytopenia (🩸 OR 0.53) without compromising PFS or OS ✅
💪Safer option, same efficacy.

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🚨 New in EJC: Prognostic impact of BRAF V600E in MSI-H mCRC on ICIs
🔗 https://t.co/5XyUSfhqJb
Retrospective, N=909
🧬 No worse PFS/OS across all lines
⚠️ Higher secondary resistance in 1L
🛡️ Dual PD-1+CTLA-4 may overcome this.
@GrupoTTD @myESMO

[Dr Amol Akhade @SuyogCancer]

D FLOT - new name
Poem at the end of presentation.
Futuristic projections in talk .
Mountain top photo.
Emphasize that it is new SOC. ( by discusant 🙂)
These all are
Good Strategy for audiance engagement .

But OS matters in stomach and GEJ cancer .

That's the HARD fact and can not be ignored @ASCO @dr_yakupergun @OncoAlert @NiuSanford @oncology_bg

[gilberto lopes @GlopesMd]

And the fun starts!
From @asco #asco25 press release

Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm.

PFS pic below @NEJM

https://t.co/mNl5uVdi87

@GlopesMd

[Arndt Vogel @ArndtVogel]

Perioperative radiochemotherapy vs Gem/Cis in locally advanced gallbladder cancers
#ASCO25
🔎POLCAGB phs-III
👉ORR 74% vs 35%
👉mEFS 10 vs 4.8 mo
👉mOS 21.8 vs 10 mo
🧐 small trial, but very interesting efficacy data in cT3/4 cN+
@myESMO @easledu @ILCAnews @curecc

[NEJM @NEJM]

Presented at #ASCO25:

In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial: https://t.co/APbBkRhcPO

@ASCO

[The Lancet Oncology @TheLancetOncol]

New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial

https://t.co/7pQ9KeJYnQ

[JAMA Oncology @JAMAOnc]

Most viewed in the last 7 days from @JAMAOnc:

Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy.

https://t.co/wt2gJY5TkZ